Interleukin 33: a suitable target for biological therapies of COPD?

Interleukin 33: a suitable target for biological therapies of COPD?

Saved in:

Bibliographic Details
Main Author:	Corrado Pelaia
Format:	Article
Language:	English
Published:	European Respiratory Society 2024-09-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/10/5/00433-2024.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease
by: Mohammad Chand Jamali, et al.
Published: (2025-05-01)

INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
by: E. G. Uchasova, et al.
Published: (2018-06-01)

Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer
by: Haoge Luo, et al.
Published: (2025-04-01)

Interleukin-33 (IL-33) as a Diagnostic and Prognostic Factor in Traumatic Brain Injury
by: Ali Kemal Erenler, et al.
Published: (2020-01-01)

Interleukin-33 and Obesity-Related Inflammation and Cancer
by: Cameron Kowitt, et al.
Published: (2024-11-01)

Colorectal carcinoma: Evaluation of systemic values of interleukin-1 and interleukin-33 in patients with and without thrombocytosis
by: Jocić Miodrag, et al.
Published: (2021-01-01)

Elevated levels of interleukin‐33 are associated with asthma: A meta‐analysis
by: Ranran Zhao, et al.
Published: (2023-04-01)

Interleukin-33/ST2: A new signaling pathway in immunity and immunopathology
by: Pavlović Slađana, et al.
Published: (2012-01-01)

Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis
by: Fabiana Furci, et al.
Published: (2025-01-01)

Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease
by: Alexis Hofherr, et al.
Published: (2024-06-01)

Predictive Significance of Interleukins 17A and 33 in Risk of Relapsing–Remitting Multiple Sclerosis
by: Milad Abdul Salam Al-Naseri, et al.
Published: (2022-12-01)

Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin.
by: Changwei Li, et al.
Published: (2014-02-01)

Serum IL-33/ST2 Axis Expression in Acute Exacerbations of COPD: Correlation with Pulmonary Function
by: Wei Y, et al.
Published: (2025-07-01)

Melatonin Attenuates Contrast-Induced Nephropathy in Diabetic Rats: The Role of Interleukin-33 and Oxidative Stress
by: Didem Onk, et al.
Published: (2016-01-01)

INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)

Biologics in COPD: The Road is Still Long and Winding
by: Konstantinos Kostikas, et al.
Published: (2025-05-01)

The Biology and Role of Interleukin-32 in Tuberculosis
by: Wu Li, et al.
Published: (2018-01-01)

Association of polymorphism of genes of folate cycle and blood serum content of interleukin-33 in patients with high summary cardiovascular risk on the combined therapy of arterial hypertension
by: I. I. Chukaeva, et al.
Published: (2014-08-01)

Evaluation of the levels of interleukins IL-4, IL-13, IL-5, IL-10 and IL-33 in atopic dermatitis patients with and without dupilumab therapy
by: Jarmila Čelakovská, et al.
Published: (2025-07-01)

Efficacy and Safety of Biologics Targeting Type 2 Inflammation in COPD: A Systematic Review and Network Meta-Analysis
by: Li S, et al.
Published: (2025-07-01)

Optimization of biological therapy selection in rheumatoid arthritis: insights into anemia and interleukin-6 pathway
by: Bora Nam
Published: (2025-01-01)

Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure
by: O. M. Drapkina, et al.
Published: (2021-10-01)

Biological pathways and mechanisms linking COPD and cardiovascular disease
by: Beatrice Ragnoli, et al.
Published: (2025-03-01)

The effects of interleukin-21 in the biology of transplant rejection
by: Xiandong Zeng, et al.
Published: (2025-05-01)

Interleukin-1 is a Biological Marker in Heart Failure
by: A. M. Alieva, et al.
Published: (2022-12-01)

Cerebrospinal fluid levels of sortilin-1, lipocalin-2, autotaxin, decorin and interleukin-33 in patients with idiopathic intracranial hypertension
by: Ahmet Dündar, et al.
Published: (2022-10-01)

Targeting interleukin-1 signaling for renoprotection
by: Daria Bogdanova, et al.
Published: (2025-05-01)

INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
by: Evgeny Lvovich Nasonov, et al.
Published: (2013-12-01)

Dual-target electrochemical aptasensor for the simultaneous detection of interleukin-6 and tumor necrosis factor-α in biological fluids
by: Maria-Bianca Irimes, et al.
Published: (2025-08-01)

Biological Functions of Interleukin-21 and Its Role in Inflammation
by: Martin Pelletier, et al.
Published: (2007-01-01)

Selection of Suitable Biological Method for the Synthesis of Silver Nanoparticles
by: Muhammad Ashraf Sabri, et al.
Published: (2016-04-01)

Aging-associated interleukin-11 drives the molecular mechanism and targeted therapy of idiopathic pulmonary fibrosis
by: Jie Zhou, et al.
Published: (2025-07-01)

Targeting of interleukin-10 receptor by a potential human interleukin-10 peptide efficiently blocks interleukin-10 pathway-dependent cell proliferation
by: Chun-Chun Chang, et al.
Published: (2020-01-01)

PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva
Published: (2016-07-01)

Combination therapy of Crohn's disease with an interleukin 12/23 inhibitor and a targeted immunosuppressant: Clinical cases
by: Oleg V. Knyazev, et al.
Published: (2025-01-01)

Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?
by: M. C. Perez-Matos, et al.
Published: (2017-01-01)

Advances in Liposomal Interleukin and Liposomal Interleukin Gene Therapy for Cancer: A Comprehensive Review of Preclinical Studies
by: Eman A. Kubbara, et al.
Published: (2025-03-01)

Targeting of the IL-33/Wnt axis restricts breast cancer stemness and metastasis
by: Guanglin Fan, et al.
Published: (2025-05-01)

Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO
by: Jianwei Hong, et al.
Published: (2025-02-01)

PROGNOSTIC VALUE OF INTERLEUKIN-6 IN VARIOUS BIOLOGICAL ENVIRONMENTS IN GENERALIZED PERITONITIS
by: N. J. Gadzhiev
Published: (2018-01-01)